New Analyses for Phase 3 Lenvatinib SELECT Study

Share this content:

the Cancer Therapy Advisor take:

According to a new analysis from the Phase 3 SELECT trial, which studied lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer, the level of baseline angiopoietin-2 may be able to be used as a predictive factor for lenvatinib response. Angiopoietin-2 is a protein that plays a role in angiogenesis. 

Another analysis from the study demonstrated a statistically significant association between hypertension and progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer being treated with lenvatinib. Hypertension is a typical adverse effect associated with vascular endothelial growth factor receptor (VEGFR) inhibition, as well as a biomarker for tyrosine kinase inhibitor (TKI) effectiveness in patients with renal cell carcinoma. In the SELECT study, researchers observed an incidence of hypertension in 73% of patients treated with lenvatinib.

A third analysis found that patients treated with lenvatinib for 1 year or more experienced a rapid tumor shrinkage within the first 8 weeks of treatment followed by a slower, continuous tumor shrinkage. In addition, findings being presented at the European Society for Medical Oncology 2014 Congress in Madrid, Spain, demonstrated a consistent progression-free survival benefit in all subgroups of the patient population examined.

Novel Therapy May Be Effective for Neuroendocrine Tumors
Baseline angiopoietin-2 may be a predictive factor for lenvatinib response in endocrine cancer.

A new analysis from the Phase III SELECT (Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid) trial of lenvatinib (E7080) in the treatment of radioiodine-refractory differentiated thyroid cancer shows that the level of baseline angiopoietin-2 may be a predictive factor for lenvatinib response and therefore tumour shrinkage and prolonged progression free survival (PFS). Angiopoietin-2 is a protein which regulates the formation of new blood vessels in tumours.

A second analysis from SELECT shows a statistically significant correlation between hypertension and PFS in people with radioiodine-refractory differentiated thyroid cancer. Hypertension is a known adverse event of vascular endothelial growth factor receptor (VEGFR) inhibition and a biomarker for tyrosine kinase inhibitor efficacy in renal cell carcinoma treatment. In the SELECT study, 73% of lenvatinib treated patients experienced hypertension.

READ FULL ARTICLE From Medical News Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs